HK1112579A1 - Dosage regimen for the treatment of a traumatic brain injury with progesterone - Google Patents

Dosage regimen for the treatment of a traumatic brain injury with progesterone

Info

Publication number
HK1112579A1
HK1112579A1 HK08107067.5A HK08107067A HK1112579A1 HK 1112579 A1 HK1112579 A1 HK 1112579A1 HK 08107067 A HK08107067 A HK 08107067A HK 1112579 A1 HK1112579 A1 HK 1112579A1
Authority
HK
Hong Kong
Prior art keywords
progesterone
treatment
brain injury
dosage regimen
traumatic brain
Prior art date
Application number
HK08107067.5A
Other languages
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellermann
Donald G Stein
David W Wright
Douglas W Lowery-North
Sarah Melissa Cutler
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of HK1112579A1 publication Critical patent/HK1112579A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
HK08107067.5A 2005-03-24 2008-06-25 Dosage regimen for the treatment of a traumatic brain injury with progesterone HK1112579A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24
PCT/US2006/010797 WO2006102596A2 (en) 2005-03-24 2006-03-24 Dosage regimen for the treatment of a traumatic brain injury with progesterone

Publications (1)

Publication Number Publication Date
HK1112579A1 true HK1112579A1 (en) 2008-09-12

Family

ID=36987966

Family Applications (3)

Application Number Title Priority Date Filing Date
HK08107067.5A HK1112579A1 (en) 2005-03-24 2008-06-25 Dosage regimen for the treatment of a traumatic brain injury with progesterone
HK08107230.7A HK1112581A1 (en) 2005-03-24 2008-06-30 Methods for the treatment of central nervous system injury via a tapered administration of progesterone
HK09107489.4A HK1128242A1 (en) 2005-03-24 2009-08-14 Indication of dosage of progesterone in the treatment of a traumatic brain injury

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK08107230.7A HK1112581A1 (en) 2005-03-24 2008-06-30 Methods for the treatment of central nervous system injury via a tapered administration of progesterone
HK09107489.4A HK1128242A1 (en) 2005-03-24 2009-08-14 Indication of dosage of progesterone in the treatment of a traumatic brain injury

Country Status (16)

Country Link
US (4) US20090325920A1 (hr)
EP (5) EP2431042B1 (hr)
JP (5) JP5295755B2 (hr)
AT (2) ATE520404T1 (hr)
AU (2) AU2006226811B2 (hr)
CA (2) CA2602950C (hr)
CY (2) CY1111478T1 (hr)
DE (1) DE602006020353D1 (hr)
DK (2) DK1868614T3 (hr)
ES (2) ES2428313T3 (hr)
HK (3) HK1112579A1 (hr)
HR (2) HRP20110198T1 (hr)
PL (2) PL1868614T3 (hr)
PT (2) PT1868614E (hr)
RS (1) RS52471B (hr)
WO (2) WO2006102644A2 (hr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006020353D1 (de) * 2005-03-24 2011-04-07 Univ Emory Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2052724A1 (en) 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
CA2716095C (en) 2008-02-26 2017-02-07 Emory University Steroid analogues for neuroprotection
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
WO2010088409A2 (en) * 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
US10231976B2 (en) 2010-02-08 2019-03-19 Prairie Pharmaceuticals LLC Methods for the use of progestogen as a glucocorticoid sensitizer
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
SG10202010665YA (en) * 2011-04-27 2020-11-27 Univ Northwestern Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
PT2806877T (pt) 2012-01-23 2019-12-06 Sage Therapeutics Inc Formulações de esteroides neuroativos que compreendem um complexo de alopregnanolona e beta-ciclodextrinas de éter sulfobutílico
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
CA2865030C (en) 2012-02-29 2021-04-27 B. Braun Melsungen Ag Hormone containing emulsion
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
IL294306B2 (en) * 2012-08-21 2024-01-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
JP6531042B2 (ja) 2013-01-29 2019-06-12 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
HRP20221545T1 (hr) 2013-01-29 2023-03-03 Aptinyx Inc. Spiro-lactam nmda receptorski modulatori i njihove uporabe
MX2015009778A (es) 2013-01-29 2016-02-09 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2015023593A1 (en) 2013-08-12 2015-02-19 Emory University Progesterone phosphate analogs and uses related thereto
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
MA43815A (fr) 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP6823083B2 (ja) 2016-05-19 2021-01-27 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
MX2019001318A (es) 2016-08-01 2019-07-01 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
BR112019001768A2 (pt) 2016-08-01 2019-06-11 Aptinyx Inc moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
IL264496B (en) 2016-08-01 2022-09-01 Aptinyx Inc Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
CA3031539C (en) 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3089561A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
US20230190709A1 (en) * 2021-12-02 2023-06-22 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
WO1989002272A1 (en) 1987-08-25 1989-03-23 Gee Kelvin W Compositions and methods for alleviating stress, anxiety and seizure activity
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
SK286051B6 (sk) * 1993-01-19 2008-02-05 Endorecherche Inc. Použitie prekurzora pohlavného steroidu na prípravu liečiva na prevenciu alebo liečenie znížených alebo nevyrovnaných koncentrácií pohlavných steroidov
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
AU7569194A (en) * 1993-08-20 1995-03-21 Meyer B. Jackson Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
KR19990022323A (ko) * 1995-06-06 1999-03-25 씨. 랜 낸시 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드
ATE267587T1 (de) * 1995-06-09 2004-06-15 Euro Celtique Sa Formulierungen und verfahren für eine verlängerte lokalanästhesie
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
WO1997043989A1 (en) 1996-05-22 1997-11-27 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
JP2001525807A (ja) 1997-05-02 2001-12-11 アメリカン・ホーム・プロダクツ・コーポレイション プレグナン−３−オール−２０−オン
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
DE602006020353D1 (de) * 2005-03-24 2011-04-07 Univ Emory Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury

Also Published As

Publication number Publication date
ES2428313T3 (es) 2013-11-07
WO2006102596A3 (en) 2007-01-18
HRP20120688T1 (hr) 2012-09-30
EP2030622A1 (en) 2009-03-04
ATE520404T1 (de) 2011-09-15
CA2601715A1 (en) 2006-09-28
JP2014055183A (ja) 2014-03-27
HK1128242A1 (en) 2009-10-23
DK1868614T3 (da) 2012-11-12
JP5394059B2 (ja) 2014-01-22
WO2006102644A3 (en) 2007-03-01
US20120245133A1 (en) 2012-09-27
JP5295755B2 (ja) 2013-09-18
RS52471B (en) 2013-02-28
CA2602950A1 (en) 2006-09-28
US20090221544A1 (en) 2009-09-03
JP5496407B2 (ja) 2014-05-21
PT2030622E (pt) 2011-06-02
HRP20110198T1 (hr) 2011-04-30
CY1113253T1 (el) 2016-04-13
WO2006102644A2 (en) 2006-09-28
EP2494976A1 (en) 2012-09-05
EP2431042A1 (en) 2012-03-21
EP1868614A2 (en) 2007-12-26
CY1111478T1 (el) 2015-08-05
ATE499104T1 (de) 2011-03-15
EP1868614B1 (en) 2012-08-08
PL2030622T3 (pl) 2011-07-29
EP2030622B1 (en) 2011-02-23
US8614203B2 (en) 2013-12-24
WO2006102644A9 (en) 2006-11-23
CA2601715C (en) 2012-10-16
AU2006226811B2 (en) 2010-11-25
JP2008534512A (ja) 2008-08-28
JP2008534515A (ja) 2008-08-28
CA2602950C (en) 2012-10-30
US20120289491A1 (en) 2012-11-15
EP1871382A2 (en) 2008-01-02
AU2006226774B2 (en) 2010-12-02
PT1868614E (pt) 2012-11-23
AU2006226774A1 (en) 2006-09-28
DK2030622T3 (da) 2011-05-02
HK1112581A1 (en) 2008-09-12
EP2431042B1 (en) 2013-06-26
DE602006020353D1 (de) 2011-04-07
ES2392454T3 (es) 2012-12-10
JP2011225629A (ja) 2011-11-10
AU2006226811A1 (en) 2006-09-28
EP1871382B1 (en) 2011-08-17
WO2006102596A2 (en) 2006-09-28
PL1868614T3 (pl) 2013-01-31
JP2013234191A (ja) 2013-11-21
US20090325920A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
HK1112579A1 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
WO2016025635A3 (en) Combination therapy for treating cancer
WO2008033792A3 (en) Repetitive transcranial magnetic stimulation for movement disorders
WO2012106444A3 (en) Methods, devices and systems for treating insomnia by inducing frontal cerebral hypothermia
EP1648385A4 (en) SYSTEM AND METHOD FOR THE PHOTODYNAMIC TREATMENT OF COMBUSTIONS, WOUNDS AND RELATED SKIN DISEASES
WO2009126931A3 (en) Therapy for bipolar disorder and mania with buprenorphine
MY202377A (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
TN2019000332A1 (en) Methods of treating pediatric cancers
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
SI1913947T1 (sl) Kombinirana terapija za zdravljenje raka
EP4269439A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
WO2016043874A3 (en) Combination therapy for treating cancer
HK1095285A1 (en) Benzamidine derivatives for treatment and prevention of mucositis
WO2017042633A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
WO2004012662A3 (en) Improved treatment of cancer with glutamine
PL370768A1 (en) Use of epothilones in the treatment of brain diseases associated with proliferative processes
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
WO2017197249A3 (en) METHODS OF TREATING HYPER-BILIRUBINEMIA USING STANNSOPORFIN AND PHOTOTHERAPY
WO2006096458A3 (en) Treatment of hyperproliferative diseases with anthraquinones
Fourianalistyawati et al. The Effectiveness of Mindfulness Technique to Decrease Pain in University Students
GB202218314D0 (en) Vitamin a for use in the treatment of traumatic brain injury
WO2005120489A3 (en) Treatment of central nervous system disorders or injuries with d-methionine
Peter Celecoxib/thalidomide/temozolomide

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CUTLER, SARAH MELISSA

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190326